66.86
1.05%
-0.71
Handel nachbörslich:
66.86
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$67.57
Offen:
$67.23
24-Stunden-Volumen:
1.78M
Relative Volume:
2.06
Marktkapitalisierung:
$10.62B
Einnahmen:
$1.17B
Nettoeinkommen (Verlust:
$150.71M
KGV:
43.99
EPS:
1.52
Netto-Cashflow:
$245.03M
1W Leistung:
-10.48%
1M Leistung:
-6.15%
6M Leistung:
-20.22%
1J Leistung:
+9.52%
Bio Techne Corp Stock (TECH) Company Profile
Firmenname
Bio Techne Corp
Sektor
Branche
Telefon
(612) 379-8854
Adresse
614 MCKINLEY PL N E, MINNEAPOLIS, MN
Vergleichen Sie TECH mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
TECH | 66.86 | 10.62B | 1.17B | 150.71M | 245.03M | 1.52 |
VRTX | 467.01 | 119.87B | 10.63B | -479.80M | -1.35B | 13.33 |
REGN | 762.00 | 83.27B | 13.85B | 4.65B | 3.32B | 35.06 |
ARGX | 567.90 | 33.96B | 1.86B | -40.29M | -1.28B | -4.16 |
ALNY | 232.27 | 30.18B | 2.09B | -332.26M | 16.06M | -4.14 |
BNTX | 101.87 | 24.42B | 3.30B | -501.07M | 1.03B | 11.54 |
Bio Techne Corp Stock (TECH) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2024-05-22 | Herabstufung | Citigroup | Buy → Neutral |
2024-02-08 | Eingeleitet | Scotiabank | Sector Outperform |
2024-02-02 | Herabstufung | Stifel | Buy → Hold |
2023-12-07 | Eingeleitet | UBS | Buy |
2023-08-28 | Eingeleitet | William Blair | Outperform |
2023-01-10 | Hochstufung | Wells Fargo | Underweight → Equal Weight |
2022-12-14 | Eingeleitet | Deutsche Bank | Buy |
2022-12-12 | Hochstufung | Citigroup | Neutral → Buy |
2022-12-07 | Eingeleitet | RBC Capital Mkts | Sector Perform |
2022-08-25 | Eingeleitet | Credit Suisse | Outperform |
2022-04-25 | Herabstufung | Wells Fargo | Equal Weight → Underweight |
2021-09-15 | Hochstufung | KeyBanc Capital Markets | Sector Weight → Overweight |
2021-03-08 | Hochstufung | Stephens | Equal-Weight → Overweight |
2021-02-23 | Hochstufung | Stifel | Hold → Buy |
2021-01-25 | Bestätigt | The Benchmark Company | Buy |
2020-11-10 | Eingeleitet | KeyBanc Capital Markets | Sector Weight |
2020-09-30 | Eingeleitet | Atlantic Equities | Overweight |
2020-07-15 | Herabstufung | Stephens | Overweight → Equal-Weight |
2020-05-27 | Herabstufung | Stifel | Buy → Hold |
2020-05-14 | Eingeleitet | The Benchmark Company | Buy |
2020-01-08 | Fortgesetzt | Stephens | Overweight |
2020-01-08 | Eingeleitet | Wells Fargo | Equal Weight |
2020-01-07 | Eingeleitet | Citigroup | Neutral |
2019-11-15 | Eingeleitet | Stifel | Buy |
2019-07-02 | Hochstufung | Janney | Neutral → Buy |
2019-01-14 | Hochstufung | Stephens | Equal-Weight → Overweight |
2018-10-31 | Herabstufung | Craig Hallum | Buy → Hold |
2018-10-17 | Eingeleitet | Goldman | Neutral |
2018-06-15 | Eingeleitet | Argus | Buy |
2017-07-13 | Eingeleitet | Wells Fargo | Market Perform |
2017-02-09 | Eingeleitet | Citigroup | Buy |
2017-01-18 | Eingeleitet | Deutsche Bank | Buy |
2016-11-10 | Fortgesetzt | Leerink Partners | Outperform |
2015-01-21 | Bestätigt | Robert W. Baird | Outperform |
2013-09-20 | Hochstufung | Robert W. Baird | Neutral → Outperform |
Alle ansehen
Bio Techne Corp Aktie (TECH) Neueste Nachrichten
BIO-TECHNE AND ALZpath ANNOUNCE STRATEGIC PARTNERSHIP TO ADVANCE NEURODEGENERATIVE DISEASE RESEARCH - Yahoo Finance
Broadcrest Asset Management LLC Has $15.99 Million Holdings in Bio-Techne Co. (NASDAQ:TECH) - MarketBeat
Royce & Associates LP Acquires 17,296 Shares of Bio-Techne Co. (NASDAQ:TECH) - MarketBeat
BIO-TECHNE TO HIGHLIGHT NOVEL SOLUTIONS FOR CANCER AND CARRIER SCREENING AT AMP 2024 ANNUAL MEETING & EXPO - Quantisnow
Geneva Capital Management LLC Has $88.27 Million Holdings in Bio-Techne Co. (NASDAQ:TECH) - MarketBeat
Sumitomo Mitsui Trust Group Inc. Cuts Stock Holdings in Bio-Techne Co. (NASDAQ:TECH) - MarketBeat
Bio-Techne To Present At UBS Global Healthcare Conference; Webcast At 12:30 PM ET - Nasdaq
Bio-Techne (NASDAQ:TECH) Raised to Buy at StockNews.com - MarketBeat
UPDATED: BIO-TECHNE ANNOUNCES IVDR CERTIFIED HEMATOLOGY CONTROLS AND CALIBRATORS - Quantisnow
BIO-TECHNE TO PRESENT AT INVESTOR CONFERENCES - Marketscreener.com
BIO-TECHNE ANNOUNCES IVDR CERTIFIED HEMATOLOGY CONTROLS AND CALIBRATORS - Quantisnow
Bio-Techne Co. (NASDAQ:TECH) is Montanaro Asset Management Ltd's 3rd Largest Position - MarketBeat
Ownership Capital B.V. Sells 208,493 Shares of Bio-Techne Co. (NASDAQ:TECH) - MarketBeat
When the Price of (TECH) Talks, People Listen - Stock Traders Daily
Bio-Techne Corporation: An Insight Into Its Market Position & Product Expansion in Diagnostics and Spatial Biology!Major Drivers - Smartkarma
Bio-Techne Gears Up for Q1 Earnings Release: What's in the Cards? - MSN
Asset Management One Co. Ltd. Has $9.69 Million Stock Position in Bio-Techne Co. (NASDAQ:TECH) - MarketBeat
ScaleReady Announces multiple G-Rex® Grants have been awarded to leading investigators at the Baylor College of Medicine's Center for Cell and Gene Therapy - Quantisnow
Bio-Techne Co. (NASDAQ:TECH) Shares Sold by Van ECK Associates Corp - MarketBeat
There May Be Some Bright Spots In Bio-Techne's (NASDAQ:TECH) Earnings - Yahoo Finance
Ex-Dividend Reminder: Bio-Techne, Pfizer and Tompkins Financial - Nasdaq
BIO-TECHNE TO PRESENT AT THE SOCIETY FOR IMMUNOTHERAPY OF CANCER (SITC) 39TH ANNUAL MEETING - WV News
Beyond the Balance Sheet: What SWOT Reveals About Bio-Techne Corp (TECH) - Yahoo Finance
Bio-Techne (FRA:TE1) Change In Receivables : €-33 Mil (TTM As of Sep. 2024) - GuruFocus.com
Bio-Techne Corporation (TECH) Announces Executive Compensation U - GuruFocus.com
Bio-Techne awards CFO restricted stock units for retention - Investing.com
TECH (Bio-Techne) 5-Year Dividend Growth Rate : 0.00% (As of Sep. 2024) - GuruFocus.com
LUNAPHORE COMET™ PLATFORM PAVES THE WAY FOR SPATIAL BIOLOGY ADOPTION IN CLINICAL RESEARCH - Quantisnow
Bio-Techne Co. (NASDAQ:TECH) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Bio-Techne Tops Q1 Earnings & Revenue Estimates, Stock Up in Premarket - MSN
Bio-Techne Corp (TECH)'s Winning Formula: Financial Metrics and Competitive Strengths - GuruFocus.com
New York State Common Retirement Fund Reduces Holdings in Bio-Techne Co. (NASDAQ:TECH) - MarketBeat
Bio-Techne (NASDAQ:TECH) Upgraded to Buy at StockNews.com - MarketBeat
9 Best Biotech Stocks Of November 2024 - Forbes
Bio-Techne Corporation (NASDAQ:TECH) Q1 2025 Earnings Call Transcript - Insider Monkey
TECH (Bio-Techne) Total Inventories : $185 Mil (As of Sep. 2024) - GuruFocus.com
Bio-Techne Tops Profit Forecasts Thanks To Booming Diagnostics - Finimize
Bio-Techne shares target raised, outperform on strong Q1 results By Investing.com - Investing.com Australia
Earnings call: Bio-Techne reports steady growth in Q1 FY2025 - Investing.com
Earnings call: Bio-Techne reports steady growth in Q1 FY2025 By Investing.com - Investing.com UK
Bio-Techne shares target raised, outperform on strong Q1 results - Investing.com India
Robert W. Baird Forecasts Strong Price Appreciation for Bio-Techne (NASDAQ:TECH) Stock - MarketBeat
Bio-Techne Corp (TECH) Q1 2025 Earnings Call Highlights: Navigat - GuruFocus.com
Bio-Techne Corp (TECH) Q1 2025 Earnings Call Highlights: Navigating Growth and Challenges in a ... - Yahoo Finance
Bio-Techne holds at $80 target with Overweight rating - Investing.com India
Bio-Techne holds at $80 target with Overweight rating By Investing.com - Investing.com South Africa
Objective long/short (TECH) Report - Stock Traders Daily
Bio-Techne Q1 25 Earnings Conference Call At 9:00 AM ET - Nasdaq
Bio-Techne beats quarterly profit estimates, driven by diagnostic unit growth; shares rise - Reuters.com
Bio-Techne Corp (TECH) Q1 FY2025 Earnings: Revenue Surpasses Est - GuruFocus.com
Bio-Techne earnings beat by $0.04, revenue topped estimates - Investing.com
Finanzdaten der Bio Techne Corp-Aktie (TECH)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):